Free Trial
NASDAQ:ZYBT

Zhengye Biotechnology (ZYBT) Stock Price, News & Analysis

$7.62 +1.85 (+32.06%)
As of 04:00 PM Eastern

About Zhengye Biotechnology Stock (NASDAQ:ZYBT)

Key Stats

Today's Range
$5.58
$8.10
50-Day Range
$3.64
$8.20
52-Week Range
$3.50
$10.00
Volume
551,435 shs
Average Volume
212,060 shs
Market Capitalization
$359.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

Remove Ads
Receive ZYBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zhengye Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

ZYBT Stock News Headlines

Zhengye Biotechnology Holding Ltd.
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).
Zhengye Biotechnology Holding Limited (ZYBT)
See More Headlines

ZYBT Stock Analysis - Frequently Asked Questions

Zhengye Biotechnology's stock was trading at $4.86 at the beginning of the year. Since then, ZYBT stock has increased by 52.9% and is now trading at $7.43.
View the best growth stocks for 2025 here
.

Zhengye Biotechnology (ZYBT) raised $6 million in an initial public offering on Tuesday, January 7th 2025. The company issued 1,500,000 shares at $4.00 per share. Kingswood Capital Partners served as the underwriter for the IPO.

Zhengye Biotechnology's quiet period expired on Monday, February 17th. Zhengye Biotechnology had issued 1,500,000 shares in its public offering on January 7th. The total size of the offering was $6,000,000 based on an initial share price of $4.00. During Zhengye Biotechnology's quiet period, insiders and any underwriters that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of ZYBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
4/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZYBT
Previous Symbol
NASDAQ:ZYBT
Fax
N/A
Employees
278
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$189.75 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$263.19 million
Optionable
N/A
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ZYBT) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners